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 Abstract  1 
Objective: Studies suggest that smoking might be a risk factor for the development of 2 
microvascular complications such as diabetic peripheral neuropathy (DPN). The objective of 3 
this study is to assess the relationship between smoking and DPN in people with type 1 or 4 
type 2 diabetes. 5 
Research Design and Methods: A systematic review of PubMed, EMBASE, and Cochrane 6 
Clinical Trials databases was conducted from 1966 to November 2014 for cohort, cross-7 
sectional and case-controlled studies that assessed the relationship between smoking and 8 
DPN. Separate meta-analyses for prospective cohort studies and case control or cross-9 
sectional studies were performed using random effects models.  10 
Results:  Thirty-eight studies (10 prospective cohort and 28 cross-sectional) were included. 11 
The prospective cohort studies included 5,558 participants without DPN at baseline. During a 12 
follow up ranging from 2 to 10 years, 1,550 cases of DPN occurred. The pooled unadjusted 13 
odds ratio (OR) of developing DPN associated with smoking was 1.26 (95% CI 0.86-1.85; 14 
I2=74.3%; Evidence grade: moderate strength). Overall prospective studies were of moderate 15 
to high quality according to the Newcastle-Ottawa scale. Including only the six studies of 16 
moderate quality, we found a higher and significant association, with an adjusted OR of 1.73 17 
(95% CI 1.48-2.03, I2=0%, Evidence grade: moderate strength). The cross sectional studies 18 
included 27,594 participants. The pooled OR of DPN associated with smoking was 1.42 19 
(95% CI 1.21-1.65; I2=64.5%; Evidence grade: moderate strength). Overall cross-sectional 20 
studies were of low to moderate quality, and after exclusion of studies of low quality (n=4), 21 
the OR was 1.29 (95% CI 1.13-1.48; I2=50.5%). There was no evidence of publication bias. 22 
Conclusions: Smoking may be associated with an increased risk of DPN in people with 23 
diabetes. Future studies are needed to test whether smoking cessation reduces the risk of DPN 24 
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 in adult with diabetes.  25 
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  Diabetic peripheral neuropathy, also known as distal symmetrical polyneuropathy or 26 
sensorimotor neuropathy, is part of a wider spectrum of microvascular complications of 27 
diabetes; other microvascular complications include ulcer/amputations, erectile dysfunction 28 
and autonomic dysfunction. Diabetic peripheral neuropathy is the most common 29 
microvascular complication of diabetes, affecting approximately 30% of people with 30 
diabetes1-3.  Symptoms include numbness, tingling or burning sensation in the legs and hands, 31 
typically in a “stocking and glove” distribution1. Ultimately, muscle weakness, loss of 32 
reflexes, and foot deformities can result, leading to end clinical sequelae of ulcers, potential 33 
infection, and amputation for some patients with poorly-controlled disease.   34 
There is a complex interaction between metabolic and vascular factors in the pathogenesis of 35 
diabetic peripheral neuropathy1,4.  Hyperglycemia has been the primary factor described  and 36 
leads to nerve-cell damage  through several mechanisms, including oxidative stress or polyol 37 
accumulation3. Reduced nerve perfusion, endoneurial hypoxia and endothelial dysfunction 38 
also contribute to neuropathy development1.  39 
Previous studies have investigated potential risk factors for diabetic peripheral neuropathy, 40 
including hypertension, microalbuminuria, dyslipidemia, and of particular interest, cigarette 41 
smoking5-7. There appears to be an increased likelihood of neuropathy in people with diabetes 42 
who smoke; however, prior studies investigating this relationship only included a small 43 
number of participants7.   44 
In order to better assess the relationship between smoking and diabetic neuropathy, we 45 
conducted a systematic review and meta-analysis, analyzing cross-sectional, case control, 46 
prospective and retrospective cohort studies.  47 
 48 
 49 
  50 
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 Research Design and Methods  51 
Search Strategy and Selection Criteria 52 
We searched PubMed (1966 to November 2014), Embase (1980 to November 2014) and 53 
Cochrane Clinical Trials (until November 2014). We also searched the references of the 54 
relevant retrieved articles. Studies that assessed the effect of cigarette smoking on the risk of 55 
peripheral neuropathy among patients with type 1 or type 2 diabetes were included 56 
(population of interest). Only participants with diabetes at baseline were included, as we were 57 
interested primarily in the effect of smoking on diabetic complications. The exposure of 58 
interest was cigarette smoking. In order to be considered for inclusion in the systematic 59 
review, all studies had to include a control or comparison group of participants with diabetes 60 
who did not smoke. The outcome of interest was diabetic peripheral neuropathy.  61 
Cohort studies as well as cross-sectional studies and case control studies were included based 62 
on our search results. For cohort studies, we included studies with at least one year of follow-63 
up because we assumed that there should be a latency period of at least one year for smoking 64 
to impact the development of diabetic neuropathy. We considered studies published in all 65 
languages and did not restrict our search to published studies only.  66 
For our search, we combined 3 search themes: 1) diabetes, 2) smoking and 3) neuropathy. 67 
The full electronic search is available in the online appendix 1.   68 
Study Selection 69 
A first screen of retrieved citations was performed based on titles and abstracts; each citation 70 
was screened by 2 different co-authors (CC, MJC, FE or KJS). The inclusion criteria for this 71 
first screen were the following: population with diabetes (type 1 or type 2) at baseline, 72 
neuropathy as one recorded outcome (not necessarily the primary outcome), and 73 
identification as prospective, cohort or cross-sectional studies. We included studies even if 74 
they did not mention smoking exposure in the title or abstract (although it was preferable). 75 
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 Exclusion criteria included gestational diabetes, animal studies, or non-original study design 76 
(such as reviews, editorials, and case reports/case series). A second screen was then 77 
performed based on full-text review of retained citations. Exclusion criteria were the same as 78 
for the first screen, with the addition of the following criteria: 1) Smoking-neuropathy 79 
relationship was not assessed and/or data did not allow calculating it by hand; 2) Peripheral 80 
neuropathy was not one of the outcomes; or 3) People without diabetes were included. 81 
 Two reviewers (CC, MJC, FE or KJS) independently reviewed the articles and any 82 
disagreement was resolved by consensus.  83 
Data Extraction and Quality Assessment 84 
Two authors independently extracted the data from selected studies. To evaluate the risk of 85 
bias in individual studies, and assess overall quality, we considered several criteria based on 86 
the Newcastle-Ottawa scale8. The Newcastle-Ottawa scale for cohort studies has 3 categories: 87 
1) selection (representativeness of the exposed cohort, selection of the non-exposed cohort, 88 
ascertainment of exposure and demonstration that outcome of interest was not present at start 89 
of study) (0-4 points), 2) comparability (comparability of cohorts on the basis of design or 90 
analyses) (0-2 points) and 3) outcome (assessment of outcome, was follow-up long enough 91 
for outcomes to occur, adequacy of follow-up of cohorts) (0-3 points). The Newcastle-Ottawa 92 
scale exists for case control studies and we used a modified version to evaluate the quality of 93 
cross-sectional studies. In the modified version we deleted the question on selection of 94 
controls (in the “selection” category, yielding to a maximum of 3 points) and the questions on 95 
methods of ascertainment for cases and controls and non-response rate (in the “exposure” 96 
section, yielding to a maximum of 2 points). We reported the score for each subcategory in 97 
the extraction form. We defined  Additionally, we evaluated the strength of evidence of the 98 
studies using the Cochrane GRADE criteria9. By definition, observational studies are 99 
considered “Low quality” with the GRADE approach. We upgraded studies to “Moderate 100 
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 quality” if they met at least one of the following factors: 1. “Large magnitude of effect”; 2. 101 
“All plausible confounding would reduce a demonstrated effect or suggest a spurious effect 102 
when results show no effect”; or 3. “Dose-response gradient”. Studies were downgraded to 103 
“Very low quality” if at least one of the following factors was present: 1. “Limitations in the 104 
design and implementation of available studies suggesting high likelihood of bias”; 2. 105 
“Indirectness of evidence”; 3. “Unexplained heterogeneity or inconsistency of results”; 4. 106 
“Imprecision of results”; or 5. “High probability of publication bias”. 107 
Studies reported risk ratios (RR), odds ratios (OR) or absolute numbers when describing the 108 
relationship between smoking and diabetic peripheral neuropathy.  As most prospective and 109 
cross-sectional studies reported ORs and not all studies provided information to convert OR 110 
into RR, we used OR in our meta-analyses. For studies that did not provide OR or RR, we 111 
calculated unadjusted ORs and Confidence intervals (CI) manually. 112 
Data Synthesis and Analysis 113 
We pooled our results using the DerSimonian and Laird random effect model10 because we 114 
expected to have heterogeneity between studies. Anticipated sources of heterogeneity 115 
included study population (people with type 1 versus type 2 diabetes), definition of smoking 116 
and definition of neuropathy and were defined a priori.  We explored other sources of 117 
heterogeneity for 3 variables that were added post-hoc: level of adjustment, mean duration of 118 
follow-up (for prospective study only) and level of quality assessed with the Newcastle-119 
Ottawa scale8. We then performed stratified analyses to assess/explore potential sources of 120 
heterogeneity linked to a priori and post hoc variables. In parallel we performed univariate 121 
metaregression analyses to quantify potential source of heterogeneity.  122 
We performed separate meta-analyses stratified by type of design. To assess heterogeneity, 123 
the Q statistic and I squared statistic were calculated11,12.  124 
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 The possibility of publication bias was assessed using the Begg test and visual inspection of 125 
the funnel plot13,14. STATA 13 (StataCorp, College Station, Texas) was used for statistical 126 
analyses.    127 
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 Results  128 
Study Selection 129 
In terms of study selection, the initial search included 2006 citations from PubMed, Embase 130 
and Cochrane Clinical Trials databases. After excluding duplicates, 1554 unique citations 131 
were available (see Figure 1). After the first screen, 126 citations were considered for further 132 
review. After a second screen, 88 studies were excluded based on full text review. Agreement 133 
between reviewers at this stage was good with a Kappa of 0.78. Reasons for exclusion at this 134 
point included no estimate (or numbers to allow manual calculation) of the smoking-135 
neuropathy relationship (n=54), outcome other than peripheral neuropathy (n = 30), or 136 
inclusion of participants without diabetes (n = 4). Finally, 38 studies were selected for final 137 
inclusion in the systematic review and we performed separate meta-analyses for the 10 138 
prospective studies5,15-23 and the 28 cross-sectional studies6,7,24-49. 139 
Smoking and incidence of diabetic peripheral neuropathy in prospective cohort studies 140 
The main individual characteristics of the prospective studies are shown in Table 1.  They 141 
include 5,558 participants in total; 3 studies include participants with type 2 diabetes, 6 142 
studies included participants with type 1 diabetes and 1 study included both participants with 143 
type 1 and type 2 diabetes. Participants were from different settings including inpatient, 144 
outpatient and the community; mean age of participants ranged from 25 to 66 years old and 145 
mean diabetes duration ranged from 0 to 17 years. All studies excluded participants with 146 
neuropathy at baseline and participants were followed for 2 to 10 years. Peripheral 147 
neuropathy screening was done by neurological history and examination in most studies5,17-148 
20,23, by electromyography to measure nerve conduction velocities in one study15, through 149 
measure of vibration perception with biothesiometers in one study22, and by monofilament 150 
examinations in two studies16,21. The definition of smoking exposure varied between studies; 151 
six studies compared ever smokers (i.e. current and former smokers) to never smokers, one 152 
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 study compared current to non smokers (i.e. former and never smokers) and 3 studies did not 153 
clearly specify the smoking comparison groups. Most studies provided OR, two RR and one 154 
gave numbers of smokers and non smokers and of participants who developed peripheral 155 
neuropathy in each category. All studies except one performed multivariable-adjusted 156 
analyses; five controlled for at least A1C and diabetes duration and 4 adjusted for either A1C 157 
or diabetes duration and several other confounders - see Online appendix 2. The quality of 158 
studies varied. Most were considered good quality with maximum points for selection and 159 
exposure criteria on the Newcastle-Ottawa scale; however, two were classified as suboptimal 160 
for quality with lower scores 15,16 . Using the GRADE criteria, two studies were rated as 161 
“Low quality”21,23, two were downgraded as “Very low”15,16 because of a poorly defined 162 
outcome and risk of selection bias, and six were upgraded to “Moderate quality”5,17-20,22 163 
mainly due to adjustment for confounding factors and a dose-response gradient. In terms of 164 
the incidence of diabetic peripheral neuropathy, 7 studies showed a positive association with 165 
smoking and 3 showed a negative association, OR ranged from 0.22 to 10.16. When we 166 
pooled the data using a random effects model, the pooled OR was 1.26 (95% CI of 0.86 – 167 
1.85) - see Figure 2. There was evidence of high heterogeneity across studies as suggested by 168 
the I-squared statistic (I2= 74.3%). Visual inspection of the funnel plot (Online appendix 3) 169 
and the Begg test (p-value = 0.72) did not suggest publication bias (i.e. no evidence of small 170 
negative unpublished studies) but showed a cluster of medium to large negative studies. 171 
Trying to correct for eventual small unpublished negative studies using the “trim and fill” 172 
method in STATA50 did not significantly change the results (OR 1.26, 95% CI 0.86-1.83). 173 
However, when restricting the analysis to studies of highest quality (i.e with “Moderate 174 
quality” using the GRADE criteria for prospective studies) the pooled OR was 1.73 (95% CI 175 
1.48-2.03) with no evidence of heterogeneity (I2= 0%) (Figure 3). In stratified analyses, 176 
studies with higher quality, better level of adjustment and longer follow-up showed a stronger 177 
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 positive association between smoking and diabetic peripheral neuropathy (Table 2). Studies 178 
including people with type 1 diabetes showed increased risks of diabetic peripheral 179 
neuropathy for smokers compared with non-smokers whereas studies with people with type 2 180 
diabetes did not show a statistically significant association between diabetic peripheral 181 
neuropathy and smoking.  182 
 183 
Smoking and prevalence of diabetic peripheral neuropathy in cross sectional studies 184 
The main individual characteristics of the cross-sectional studies are shown in Table 3.  They 185 
include 27,594 participants in total; 21 studies include people with type 2 diabetes, 3 with 186 
type 1 diabetes and 4 with both type 1 and type 2 diabetes. Mean age of participants ranged 187 
from 19 to 68 years old and mean diabetes duration ranged from 0 to 20 years. There was a 188 
high heterogeneity in the definition of exposure: 7 studies compared current smokers to non 189 
smokers (i.e. former and never smokers), 4 studies compared ever smokers (i.e. current and 190 
former smokers) to never smokers, 6 studies compared current vs. never smokers, 2 studies 191 
compared smokers of 30 or more pack-years to smokers of less than 30 pack-years, one study 192 
compared smokers of < 20 pack years to never smokers and 8 studies did not specify the 193 
comparison groups. The majority of studies expressed the estimate in OR, two used RR and 9 194 
used number or proportions, allowing us to calculate unadjusted OR and 95% CI manually. 195 
Seven studies controlled for at least A1C and diabetes duration, one adjusted for either A1C 196 
or diabetes duration, 4 adjusted for some confounders but not A1C and diabetes duration and 197 
16 did not adjust for potential confounders.- see Online appendix 4. Using the GRADE 198 
criteria, most studies were rated as “Low quality” and 4 studies were downgraded as “Very 199 
low”25,28-30 mainly because of selection bias, lack of adjustment for confounders and poorly 200 
defined exposure and/or outcome. The majority of studies showed increased odds of 201 
neuropathy for smokers compared with non-smokers and ORs ranged from 0.68 to 8.20. The 202 
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 pooled OR using a random effects model was 1.42 (95% CI of 1.21 – 1.65) - see Figure 4. 203 
There was evidence of some heterogeneity between studies (I2 = 64.5%). There was no 204 
evidence of publication bias as suggested by both visual inspection of the funnel plots 205 
(Online appendix 5) and the Begg test (p-value = 0.17). In stratified analyses, studies with 206 
higher level of adjustment, studies which included participants with type 1diabetes and those 207 
comparing ever vs. never smokers showed a higher and stronger association between 208 
smoking and diabetic peripheral neuropathy. (Table 2) When analyses were restricted to 209 
studies with the highest available level of evidence (i.e. “Low quality” using the GRADE 210 
criteria) the pooled OR was 1.29 (95% CI 1.13-1.48; I2=50.5%). When analyzing only studies 211 
which provided adjusted estimates OR was 1.59 (95% CI 1.28-1.97, I2=43.4%). 212 
 213 
 214 
Conclusions  215 
In summary, we found a positive association between smoking and diabetic peripheral 216 
neuropathy prevalence and incidence. Although we performed two different meta-analyses, 217 
both had similar findings and suggest that smoking is associated with an increased risk of 218 
peripheral neuropathy among people with diabetes. There was substantial heterogeneity for 219 
both prospective and cross-sectional meta-analyses. However, in stratified analyses, studies 220 
with higher level of adjustment, longer follow-up (prospective studies only) and good level of 221 
quality showed a stronger positive association between smoking and diabetic peripheral 222 
neuropathy with less heterogeneity. Prospective studies comparing ever smokers (current and 223 
former smokers) vs. never smokers as well as those including participants with type 1 224 
diabetes showed a stronger positive association between smoking and diabetic peripheral 225 
neuropathy. However these studies were of higher quality and might not necessarily reflect a 226 
real effect modification.  227 
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  228 
In people without diabetes, cigarette smoking has been shown to be positively associated 229 
with A1C, a surrogate for metabolic control which reflects average glycemia over the past 230 
months51. A previous meta-analysis has shown that smokers have a 44% increased risk of 231 
developing type 2 diabetes compared with non smokers52. Among people with diabetes prior 232 
studies suggest that smoking is also associated with insulin resistance53, higher insulin 233 
needs54,55 and thus poor metabolic control56-61.  As microvascular complications in people 234 
with type 1 or type 2 diabetes are highly linked to metabolic control62,63, A1C probably acts 235 
as a mediator in the relationship between smoking and diabetic peripheral neuropathy. 236 
However, the fact that the association remains positive after adjustment for A1C suggests that 237 
hyperglycemia may not entirely mediate this relationship. Furthermore, smoking is associated 238 
with oxidative stress, systemic inflammation and endothelial dysfunction independent of 239 
diabetes64-66. It might increase the risk of nerve damage through these pathways in parallel to 240 
metabolic factors.  Smoking may also have direct toxic effects and induce diabetic peripheral 241 
neuropathy via hypoxemia and microvascular insufficiency. Similar to what occurs with 242 
larger vessels (coronary arteries), smaller arteries, including vasa nervorum, might be 243 
damaged by smoking which, in turn, leads to development and progression of diabetic 244 
peripheral neuropathy. Smoking has been found to be a causal variable in other microvascular 245 
complications such as retinopathy or nephropathy, and similar mechanisms might occur for 246 
diabetic peripheral neuropathy to damage those target organs67. Finally, confounding factors 247 
might also contribute to the association between smoking and diabetic peripheral neuropathy. 248 
Smokers might have poorer adherence to recommended self-care compared with non-249 
smokers68. Smokers also tend to accumulate unhealthy behaviors such as alcohol abuse, lack 250 
of physical activity or a diet rich in fat and poor in fruits and vegetables69. Though these 251 
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 factors might contribute to diabetes complications through poorer diabetes control, they do 252 
not entirely explain the association, which remains after adjustment for diabetes control.   253 
 254 
Our study has several strengths. We retrieved and pooled a substantial number of studies, 255 
assessing the association between smoking and diabetic peripheral neuropathy. Contrary to 256 
other microvascular complications such as nephropathy or retinopathy, few studies had to 257 
date shown a clear positive association between smoking and diabetic peripheral neuropathy. 258 
Indeed, few studies have been directly designed to measure the impact of smoking on 259 
diabetic peripheral neuropathy and the complex, multifactorial pathogenesis of diabetic 260 
peripheral neuropathy makes it difficult to measure the effect of smoking on a unique 261 
outcome. Many prospective studies and some cross-sectional studies, included in our meta-262 
analysis, provided adjusted estimates which permitted control for some potential confounders 263 
and exploration of mediating factors. 264 
 265 
Our study has several limitations including the relatively small number of prospective studies 266 
and the heterogeneity between studies. Stratified analyses allowed us to address the source of 267 
heterogeneity but due to limited number of prospective studies, some conclusions cannot be 268 
drawn. For example, studies including participants with type 1 diabetes were of higher 269 
quality, and it is thus difficult to conclude that the association between smoking and diabetic 270 
peripheral neuropathy is significant only among people with type 1 diabetes and not in those 271 
with type 2 diabetes. Another limitation is that the cross-sectional studies were of medium to 272 
poor quality. Some did not adjust for the main confounders, some did not assess the outcome 273 
clinically, and the smoking exposure was very variable between studies. Finally, we cannot 274 
prove that the association we observed is causal because of the design and limitations of our 275 
selected studies.  276 
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  277 
Few studies have prospectively assessed the impact of smoking cessation on diabetes control 278 
and complications. We identified only one study which prospectively assessed the impact of 279 
smoking cessation on diabetic peripheral neuropathy 70. Among 193 participants newly 280 
diagnosed with type 2 diabetes and microalbuminuria, 62% had quit smoking at 12 months. 281 
In this population, the prevalence of diabetic peripheral neuropathy decreased significantly 282 
more in participants who quit smoking compared to those who continued (p < 0.04), but no 283 
absolute numbers were given. This was also the case for microalbuninuria, peripheral 284 
vascular disease, blood pressure and dyslipidemia. This unique study of suboptimal quality 285 
suggests that the effect of smoking on diabetic peripheral neuropathy might be reversible, but 286 
more research is needed to assess the effect of smoking cessation on diabetes control and 287 
micro-vascular complications.  288 
In conclusion, smoking might be associated with an increased risk of developing diabetic 289 
peripheral neuropathy. This is an important finding as this exposure is a modifiable behavior 290 
to be targeted in clinical practice,  as recommended in diabetes guidelines71. Even though we 291 
cannot exclude the possibility of confounding, it seems reasonable based on the consistency 292 
of results and plausibility of biological hypothesis that the association might be causal or at 293 
least of concern for clinicians. Future research should be focused on evaluating the impact of 294 
smoking cessation on improvement of diabetic neuropathy, helping to establish a causal link 295 
between exposure and outcome. 296 
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 Table 1: Characteristics of prospective studies included in the Meta-analysis 
Author, year Country/ 
region 
Sample 
size 
Population Type 
of DM 
% 
men 
Mean 
age  
Mean DM 
duration 
Neuropathy 
screening 
Smoking 
comparison 
FUP 
y 
Estimate 
Lehtinen et al., 
1993 Finland 113 
Subjects with 
newly diagnosed  
DM from the 
community 
2 51 56.4 0 
Nerve 
conduction 
velocities 
NS  5 N 
Adler et al., 
1997 USA 387 
US veterans 
followed in an 
outpatient clinic 
Both 96 61.7 9.8 Monofilament examination 
Current vs. 
former + 
never 
smokers 
2.6 OR 
Forrest et al., 
1997 USA 453 
Subjects with 
childhood-onset 
DM 
1 49 25.1 16.9 Neurological examination 
Current + 
former vs. 
never 
smokers 
5.3 RR 
Sands et al., 
1997 USA 231 
Biethnic 
population in 
Colorado 
2 NS NS NS 
Neurological 
examination 
and history 
Current + 
former vs. 
never 
smokers 
4.7 OR 
Christen et al., 
1999 USA 407 
Participants of a 
drug (Sorbinil) 
multi-center trial  
1 75 31.4 6.5 
Neurological 
examination 
and history 
Current + 
former vs. 
never 
smokers* 
2 RR 
Tesfaye et al., 
2005 Europe 1172 
Subjects 
randomly 
selected from 31 
diabetes clinics 
1 51 30.7 12.4 Neurological examination 
Current + 
former vs. 
never 
smokers 
7.3 OR 
Sibal et al., 
2006 UK 334 
Outpatients who 
attended diabetes 
services 
1 54 39 20 
Neurological 
examination 
and history 
NS 9 OR 
Gerrits et al., Netherlands 973 Subjects from 2 46 66 4 Monofilament NS 3.1 OR 
 
  
DM = diabetes mellitus, NS = non specified, FUP = follow-up, OR=Odds ratio, RR=Relative risk, N=number or proportion 
* In the age-adjusted analyses, compared current smokers to never smokers, in the multivariable-adjusted model compares ever to never 
smokers 
 
  
2008 primary care examination 
Elliott et al.,  
2009 Europe 1407 
Subjects 
randomly 
selected from 31 
diabetes clinics 
1 48 31.5 13.1 
Vibration 
perception 
threshold 
measured by 
biothesiometers 
Current + 
former vs. 
never 
smokers 
7.3 OR 
Uruska et al., 
2014 Poland 81 
Patients treated 
with intensive 
Insulin from 
onset of disease 
1 63 34 10 
Neurological 
examination 
(monofilament, 
vibration, 
temperature 
and ankle 
reflex) 
Current + 
former vs. 
never 
smokers 
10 OR 
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 Table 2: Stratified analyses for prospective and cross-sectional studies 
Stratified analysis Total number of trials OR (95% CI) I-squared 
P value from 
metareg+ 
Adjustment for confounding factors      
Prospective studies     0.71 
   Adjusted for at least HbA1c and DM duration 5 1.47 (1.01-2.13) 71.8%  
   Not adjusted for HbA1c and DM duration 5 1.03 (0.34-3.09) 79.2%  
Cross sectional studies     0.31 
   Adjusted for at least HbA1c and DM duration 7 1.59 (1.23-2.06) 43.6%  
   Not adjusted for HbA1c and DM duration 21 1.36 (1.11-1.66) 69.2%  
Type of diabetes      
Prospective studies     0.02 
   Type 1 6 1.74 (1.48-2.04) 0%  
   Type 2 3 0.65 (0.16-2.71) 83.2%  
   Both 1 0.22 (0.07-0.66) --  
Cross sectional studies     0.19 
   Type 1 3 3.02 (2.03-4.47) 11.7%  
   Type 2 21 1.24 (1.08-1.44) 50.5%  
   Both 4 1.55 (0.94-2.57) 63.2%  
Smoking exposure      
Prospective studies     0.007 
   Ever (current + former) vs. never smoker 6 1.77 (1.51-2.08) 0%  
   Current vs. never smoker 1 0.22 (0.07-0.66) --  
   Non specified 3 0.47 (0.21-1.06) 31.6%  
Cross sectional studies     0.79 
   Ever (current + former) vs. never smoker 4 1.78 (1.39-2.29) 10.6%  
   Current vs. non smokers (former + never) 7 1.38 (0.87-2.20) 70.0%  
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    Current vs. never smoker 6 1.58 (1.00-2.48) 74.2%  
   Non specified or other definition 11 1.28 (1.03-1.60) 57.2%  
Mean follow-up      
Prospective studies     0.322 
   < 5 years 4 0.77 (0.25-2.31) 86.4%  
   ≥ 5 years 6 1.63 (1.21-2.21) 47.7%  
Level of quality (GRADE criteria)      
Prospective studies     0.007 
   Moderate  6 1.73 (1.48-2.03) 0%  
   Low   2 1.57 (0.05-50.83) 91%  
   Very low  2 0.27 (0.11-0.65) 0%  
Cross sectional studies     0.75 
   Low  22 1.29 (1.13-1.48) 50.5%  
   Very low  4 1.30 (0.61-2.75) 68.3%  
 
+ P-value for metaregression using the “metareg” Stata command  
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 Table 3: Characteristics of cross-sectional studies included in the Meta-analysis 
Author Country Sample 
size 
Population Type 
of 
DM 
% 
men 
Mean 
age  
Mean 
DM 
duration 
Neuropathy 
screening 
Smoking 
measure 
Estimate 
Maser et al., 
198966666666666666666
66 USA 363 
Cohort of patients 
with recent diagnosis 1 50 28.4 19.9 
Neurological 
examination and 
history 
Current + 
former vs. 
never 
smokers 
OR 
Mitchell et al., 
1990 USA 214 
Patients admitted to 
the inpatient diabetic 
clinic of a University 
hospital 
1 37 46 14.7 
Neurological 
examination and 
history 
Smoking ≥ 30 
vs. < 30 pack-
years 
OR 
Franklin et al., 
1994 USA 277 Biethnic population in Colorado 2 43 59.5 9.7 
Neurological 
examination and 
history 
< 20 pack-
years vs. 
never 
smokers 
OR 
Gregory et al., 
1994 UK 136 
Newly diagnosed 
patients attending a 
hospital 
2 50 68 0 
Neurological 
examination and 
history 
Smoking ≥ 30 
vs. < 30 pack-
years 
N 
Matsumoto et 
al., 
1994 Japan 742 
Outpatients who 
visited the diabetic 
unit of a department 
of internal medicine 
2 54 49 1.3 
Information from 
patient's charts 
and neurological 
examination t 
NS OR 
Zafra Mezcua 
et al., 
2000 
Spain 504 
Patients attending a 
medical outpatient 
clinic 
2 42 63.9 8.6 Medical chart review NS RR 
Barbosa et al., 
2001 Portugal 93 Patients from primary health cares 2 40 65.4 10.1 
Neurological 
examination 
Current vs. 
never 
smokers 
N 
Gomez-Viera et 
al., Cuba 200 
Patients diagnosed  in 
clinic Both 37 . . 
Clinical diagnosis 
with NS RR 
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 2001 neuroinduction 
exam 
corroboration 
Tapp et al., 
2003 Australia 821 Population-based survey 2 51 63.1 0.2 
Neurological 
examination and 
history 
Current vs. 
former + 
never 
smokers 
OR 
Boru et al., 
2004 Turkey 866 
Patients who 
attended a diabetic 
clinic 
2 40 57.2 8.5 
Neurological 
examination and 
history 
NS OR 
Tamer et al., 
2006 Turkey 191 Patients with type 2 DM recruited 2 43 58.7 . 
Neurological 
examination and 
electromyography 
Current + 
former vs. 
never 
smokers 
OR 
Al-Mahroos et 
al., 
2007 
Bahrain 1477 Patients from specialized clinics 2 43 57.3 9.5 
Neurological 
examination and 
history 
NS OR 
Cho et al., 
2010 Korea 90 
Patients who 
underwent work-ups 
for peripheral 
polyneuropathy 
2 51 59 8.7 
Neurological 
examination and 
history 
NS OR 
Jianbo  
et al., 
2011 China 227 
Inpatients and 
outpatients 2 . 64.5 9.3 
Neurologic exam 
and 
electromyography 
 
Current vs. 
never smoker N 
Spallone et al., 
2011 Italy 191 
Diabetic patients with 
suspected 
neuropathic pain 
referred to a center 
Both 56.5 58.6 16.7 
History + 
electrodiagnostic 
studies in selected 
cases 
NS OR 
Wang et al., 
2011 USA 816 
Patients referred to a 
diabetes education 
program 
2 45.2 57 . 
Questionnaires 
and review of 
medical records 
Current + 
former vs. 
never 
OR 
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 smokers 
Abougalambou 
et al., 
2012 Malaysia 1077 
Patient followed in an 
outpatient diabetic 
clinic 
2 45.2 . . Neurologic exam 
Current vs. 
former+ 
never 
smokers 
OR 
Ji et al., 
2012 China 565 Mostly inpatients 2 47.8 66.6 16.2 
Medical history 
and/or symptoms 
and/or 
neurological exam 
Current vs. 
never 
smokers 
N 
Katulanda et 
al., 
2012 Sri Lanka 337 
Non institutionalized 
adults from the 
community 
2 37.1 56.8 6.3 Symptoms and neurologic exam 
Current vs. 
former + 
never 
smokers 
OR 
Rasul et al., 
2012 Austria 120 Patients from an outpatient clinic 2 59.2 62.9 12.7 
Neurological exam 
and nerve 
conduction 
velocity 
Current vs. 
never 
smokers 
N 
Eleftheradiou 
et al.,  
2013 
(Abstract) Greece 71 Patients from an outpatient clinic 2 63.4 67.7 15 
Neuropathy 
symptom and 
neuropathy 
disability scores,  
vibration 
perception 
threshold 
Current vs. 
former + 
never 
smokers 
OR 
Molina et al., 
2013 Spain 405 
Patients from a 
diabetes clinic and 
primary care clinic 
2 58.3 66 12.7 
Semmes-
Weinstein 
monofilament test 
Current vs. 
former + 
never 
smokers 
N 
Aubert et al., 
2014 France 198  2 79.8 65 13 
Neuropathy 
disability score or 
inability to 
perceive 
Current vs. 
former + 
never 
smokers 
N 
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DM = diabetes mellitus, NS = non specified, FUP = follow-up, OR=Odds ratio, RR=Relative risk, N=number or proportion 
  
monofilament 
 
Bener et al.,  
2014 Qatar 1633  Both 51.6 45.3 7.3 Not specified 
Current vs. 
former + 
never 
smokers 
OR 
Brownrigg et 
al., 
2014 
UK 13043  2 51.8 63.8 . 
Semmes-
Weinstein 
monofilament test 
Current vs. 
never 
smokers 
N 
Hu et al., 
2014 China 937 
Diabetic inpatients 
ate a clinical medical 
center of diabetes 
2 57.7 59.6 9.8 
Neurological 
examination and 
nerve conduction 
tests 
NS N 
Jaiswal et al., 
2014 
(Abstract) USA 1448 
Participants to the 
SEARCH for 
diabetes in youth 
study 
1 50 19 8 Symptoms and neurologic exam 
Current vs. 
never 
smokers 
OR 
Wang et al., 
2014 Saudi 
Arabia 552 
People with diabetes 
from the community Both 62.7 53.4 .  
Current + 
former vs. 
never 
smokers 
OR 
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 Figure 1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2006  Records identified through database      
searching (PubMed, Embase, and 
Cochrane) 
 
1554  Records after duplicates removed  
 
1554  Records screened  1429 Records excluded  
126  Full-text articles           
assessed for eligibility  
88  Excluded based on full-             
text review                                
54   Smoking neuropathy              
relationship not assessed                          
30   Outcome is not 
Peripheral neuropathy      
4     People without 
diabetes included  
 
38  Studies included in           
meta-analysis  
 
10  Prospective cohort   
        
  
28  Cross-sectional studies  
 
 
 Figure 2 
 
Dashed vertical line represents the estimated pooled effect size estimate; points in grey squares with lines represent odds ratios and 95% CIs of individual 
studies; the open diamond represent a visual summary of the overall 95% CI of the effect estimate of smoking on the incidence of DPN. Studies on the right 
of the 1 vertical line indicate a positive association between smoking and DPN, studies on the left a negative association. 
 
 Figure 3 
 
Dashed vertical line represents the estimated pooled effect size estimate; points in grey squares with lines represent odds ratios and 95% CIs of individual 
studies; the open diamond represent a visual summary of the overall 95% CI of the effect estimate of smoking on the incidence of DPN. Studies on the right 
of the 1 vertical line indicate a positive association between smoking and DPN, studies on the left a negative association. 
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 Figure 4 
 
Dashed vertical line represents the estimated pooled effect size estimate; points in grey squares with lines represent odds ratios and 95% CIs of individual 
studies; the open diamond represent a visual summary of the overall 95% CI of the effect estimate of smoking on the prevalence of DPN. Studies on the 
right of the 1 vertical line indicate a positive association between smoking and DPN, studies on the left a negative association.  
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 Online appendix 1 
 
A) Electronic search strategy for PubMed (performed on November 17, 2014): 
 
 ((polyneuropath*[tiab] OR neuropath*[tiab]) OR ("Peripheral Nervous System 
Diseases"[Mesh]) OR ((("Diabetic Neuropathies"[Mesh]) OR "Polyneuropathies"[Mesh]) OR 
"Diabetic Foot"[Mesh])) AND (("Diabetes Mellitus, Type 2"[Mesh] OR "Diabetes Mellitus, 
Type 1"[Mesh]) OR (diabetes[tiab] OR diabetic*[tiab])) AND (((("Smoking"[Mesh] OR 
"Smoking Cessation"[Mesh]) OR ("Tobacco Use Cessation"[Mesh] OR "Tobacco Use 
Disorder"[Mesh] OR "Tobacco, Smokeless"[Mesh] OR "Tobacco"[Mesh])) OR 
"Nicotine"[Mesh]) OR (smoking[tiab] OR smoker*[tiab] OR cigarett*[tiab] OR tobacco[tiab] 
OR nicotine[tiab])). 
B) Electronic search strategy for Embase (performed on November 17, 2014): 
 
'diabetic neuropathy'/exp OR 'peripheral 
neuropathy'/exp OR 'polyneuropathy'/exp AND 
[embase]/lim  
'diabetes mellitus'/exp OR 'non insulin 
dependent diabetes mellitus'/exp OR 'insulin 
dependent diabetes mellitus'/exp AND 
[embase]/lim  
'smoking'/exp OR 'smoking cessation'/exp OR 
'smokeless tobacco'/exp OR 'tobacco 
dependence'/exp OR 'tobacco'/exp OR 
'nicotine'/exp AND [embase]/lim  
 
 
 
 Online appendix 2: Level of adjustment and quality of prospective studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HbA1c= glycated heamoglobin, DM=diabetes mellitus 
Author, year Adjustment Quality score (NOS scale) Selection1 Comparability2 Exposure3 
Lehtinen et 
al., 
1993 
- *** - ** 
Adler et al., 
1997 
HbA1c, height, history of ulcer, age, alcohol, albumin, 
creatinin * * * 
Forrest et al., 
1997 HbA1c, DM duration, height, hypertension **** ** *** 
Sands et al., 
1997 
HbA1c, DM duration, age, insulin treatment, ethnicity, 
gender, history of myocardial infarct, angina **** ** *** 
Christen et 
al., 
1999 
HbA1c, age, drug (Sorbinil vs plabebo), height, 
gender **** * *** 
Tesfaye et al., 
2005 HbA1c, DM duration **** * *** 
Sibal et al., 
2006 
DM duration, systolic blood pressure, diastolic blood 
pressure, total cholesterol, glomerular filtration rate, 
triglycerides, microalbuminuria, retinopathy, foot 
complications 
**** * *** 
Gerrits et al., 
2008 
HbA1c, DM duration, sex, systolic blood pressure, 
LDL cholesterol, HDL cholesterol, triglycerides, body-
mass index, skin autofluorescence 
**** ** *** 
Elliott et al.,  
2009 
HbA1C, DM duration, hypertension, body-mass index, 
retinopathy, cardiovascular disease history, 
cholesterol, triglycerides, albumin 
**** * *** 
Uruska et al., 
2014 HbA1c, age, sexe, hypertension *** * * 
 
 NOS scale = Newcastle Ottawa scale 
1 Selection : minimum = -, maximum =****, 2 Comparability: minimum = -, maximum = **, 3 Exposure: minimum = -, maximum = *** 
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 Online appendix 3 
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 Online appendix 4:  Level of adjustment and quality of cross-sectional studies 
Author, year Adjustment Quality score (NOS scale) Selection1 Comparability2 Exposure3 
Maser et al., 
1989666666666666666
666666 
HbA1c,DM duration, HDL-cholesterol, 
macrovascular disease * ** * 
Mitchell et al., 
1990 HbA1c, DM duration * * * 
Franklin et al., 
1994 
HbA1c, DM duration, age, ethnicity, systolic 
blood pressure, height, insulin use, alcohol, 
serum lipids, peripheral vascular disease, 
fasting C-peptide   
* ** * 
Gregory et al., 
1994 - * - * 
Matsumoto et 
al., 1994 - ** - ** 
Zafra Mezcua et 
al., 2000 - *** - * 
Barbosa et al., 
2001 - * - * 
Gomez-Viera et 
al., 
2001 
- * - * 
Tapp et al., 
2003 - * - * 
Boru et al., 
2004 
HbA1c, DM duration, retinopathy, 
hypertension, hyperlipidemia, alcohol * ** * 
Tamer et al., 
2006 
HbA1c, DM duration, gender, age, 
hypertension, cholesterol, triglycerides, drug 
usage, neuropathic complaints 
* ** * 
Al-Mahroos et 
al., 2007 
HbA1c, DM duration, gender, age, 
hypertension, cholesterol, triglycerides, body-
mass index, waist circumference  
* ** * 
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 Cho et al., 
2010 
Retinopathy, systolic blood pressure, diastolic 
blood pressure, gamma-glutamyl transferase, 
Aspartate amino transferase, urine 
albunine/creatinie, C-reactive protein 
* * * 
Jianbo et al., 
2011 - *** - * 
Spallone et al., 
2011 
HbA1c, DM duration, gender, age, systolic 
blood pressure, triglycerides, peripheral 
arterial disease, Valsalva ratio, type of DM, 
body-mass index, waist circumference , 
Michigan Diabetic Neuropathy Score 
* ** * 
Wang et al., 
2011 
DM duration, sex, race, education, self foot 
exam, foot exam by medical doctor * * * 
Abougalambou 
et al., 2012 - *** - * 
Ji et al., 2012 - *** - * 
Katulanda et 
al., 2012 - *** - * 
Rasul et al., 
2012 - *** - * 
Eleftheradiou et 
al., 2013 
(abstract) 
Sex, age,  body-mass index    
Molina et al., 
2013 - ** - ** 
Aubert et al., 
2014 - *** - ** 
Bener et al., 
2014 - ** - * 
Brownrigg et 
al., 2014 - **** - ** 
Jaiswal et al., 
2014 (abstract) -    
Hu et al., 2014 - ** - ** 
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HbA1c= glycated 
heamoglobin, DM=diabetes mellitus, NA= not applicable 
NOS scale = Newcastle Ottawa scale 
1 Selection : minimum = -, maximum =***, 2 Comparability: minimum = -, maximum = **, 3 Exposure: minimum = -, maximum = ** 
 
 
 
 
 
 
 
 
 
 
 
 
 
Online appendix 5 
Wang et al., 
2014 Sex, age, nationality *** * * 
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